논문 및 특허

항암치료기술의 새로운 미래를 열어가는카스큐어 테라퓨틱스(주)
논문 및 특허

[논문] Precision targeting tumor cells using cancer-specific InDel mutat…

페이지 정보

작성자 최고관리자 작성일25-06-22 19:20 조회180회 댓글0건
연락처 이메일 interfish@naver.com

본문

DOI: 10.1073/pnas.2103532119


Abstract

An ideal cancer therapeutic strategy involves the selective killing of cancer cells without affecting the surrounding normal cells. However, researchers have failed to develop such methods for achieving selective cancer cell death because of shared features between cancerous and normal cells. In this study, we have developed a therapeutic strategy called the cancer-specific insertions–deletions (InDels) attacker (CINDELA) to selectively induce cancer cell death using the CRISPR-Cas system. CINDELA utilizes a previously unexplored idea of introducing CRISPR-mediated DNA double-strand breaks (DSBs) in a cancer-specific fashion to facilitate specific cell death. In particular, CINDELA targets multiple InDels with CRISPR-Cas9 to produce many DNA DSBs that result in cancer-specific cell death. As a proof of concept, we demonstrate here that CINDELA selectively kills human cancer cell lines, xenograft human tumors in mice, patient-derived glioblastoma, and lung patient-driven xenograft tumors without affecting healthy human cells or altering mouse growth.